Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Who Took Part

According to the abstract, 21,315 participants were involved.

The age groups tagged for this paper are older adults.

Computer generated permuted block randomisation was used to allocate treatments.

21 315 participants aged 60-84 years at enrolment.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Australia from 2014 to 2020.

What Was Measured

The subject headings attached to it are Vitamins, Cardiovascular Agents, Vitamin D, Myocardial Infarction and Dietary Supplements.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 21,315 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (BMJ (Clinical research ed.)), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.